Fidaxomicin Dosage

Medically reviewed by Drugs.com. Last updated on Jan 6, 2025.

Applies to the following strengths: 200 mg; 40 mg/mL

Usual Adult Dose for Clostridial Infection

200 mg orally twice a day for 10 days

Use: For the treatment of Clostridioides difficile-associated diarrhea (CDAD)

Usual Pediatric Dose for Clostridial Infection

6 Months to Less Than 18 Years:
Oral suspension:

Weight 4 to less than 7 kg: 80 mg orally twice a day
Weight 7 to less than 9 kg: 120 mg orally twice a day
Weight 9 to less than 12.5 kg: 160 mg orally twice a day
Weight at least 12.5 kg: 200 mg orally twice a day

Tablets:

Weight at least 12.5 kg: 200 mg orally twice a day

Duration of therapy: 10 days

Use: For the treatment of CDAD

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
Known hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 6 months.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

Administer with or without food.
Administer tablets to pediatric patients weighing at least 12.5 kg and able to swallow tablets; if unable to swallow tablets, may administer the oral suspension
Remove the oral suspension from the refrigerator 15 minutes before each administration.
Shake the oral suspension vigorously until consistency is even.
Use an oral dosing syringe to administer the oral suspension.

Storage requirements:

Granules for oral suspension: Store in original package at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F); do not open pouch until time of use.
Reconstituted oral suspension: Store capped in original bottle in refrigerator at 2C to 8C (36F to 46F) for up to 12 days; discard after 12 days.
Tablets: Store in original bottle at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).

Reconstitution/preparation techniques:

Oral suspension: The manufacturer product information should be consulted.

General:

To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat infections proven or strongly suspected to be caused by C difficile.
Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice: